ArticleSignal transduction and targeted therapy2026
Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Switching tumor-derived extracellular vesicles off and on via targeted proteolysis to shift toward immunogenic phenotypes.Signal transduction and targeted therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Tumor cell-derived small extracellular vesicles (TDEs) play a critical role in immune evasion, including the establishment of an immunosuppressive tumor microenvironment (TME), and form a substantial barrier to effective cancer immunotherapy. Here, we introduce the ExoPERM (pH-enabled rupture of exosome membranes) strategy, a pH-responsive system based on small extracellular vesicle (EV)-disrupting alpha-helical peptides that selectively target small EVs localized within the TME. By incorporating a pH-sensitive linker through PEGylation, this system ensures systemic stability while allowing the selective release of peptides within the mildly acidic TME. Mechanistic investigations revealed that the peptide preferentially ruptured small EVs at pH 6.5, effectively preventing EVs' PD-L1 interactions with PD-1 on CD8⁺ T cells and contributing to the restoration of their effector functions. Furthermore, this targeted disruption significantly attenuated TDE-induced activation of cancer-associated fibroblasts, thereby remodeling the dense fibrotic stroma that physically restricts immune cell penetration. In vivo studies have demonstrated enhanced CD8⁺ T-cell tumor infiltration and activation, notably when combined with immune checkpoint blockade or adoptive T-cell transfer. These synergistic effects were robustly validated across murine melanoma and colorectal cancer models, successfully converting immunologically cold tumors into T-cell-inflamed hot tumors. The ExoPERM strategy provides a promising option for overcoming TDE-mediated resistance in cancer, suggesting a distinct approach to small EV inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.